医学
达托霉素
内科学
利奈唑啉
中止
耐万古霉素肠球菌
肝硬化
胃肠病学
回顾性队列研究
外科
万古霉素
遗传学
生物
细菌
金黄色葡萄球菌
作者
Aldo Barajas‐Ochoa,Olivia Hess,Tucker John Guy Smith,Matthew Ambrosio,Megan K. Morales,Idris Yakubu,Lora D. Thomas,David Bruno,Nicole Vissichelli
摘要
Abstract Introduction Vancomycin‐resistant Enterococci (VRE) infections cause significant morbidity and mortality in liver transplant (LT) recipients. Management is challenging, especially in the setting of daptomycin resistance (DR). Methods Single‐center retrospective review of patients who underwent LT between January 1, 2020, and December 31, 2022, and developed VRE infections. Descriptive statistics were used and Kaplan‐Meier curves estimated freedom from treatment failure and survival. Results Forty‐two patients (median age 58; 64% female; 67% white) were included. Alcohol‐related cirrhosis (48%) and metabolic dysfunction‐associated steatohepatitis (31%) were the most common indications for LT, and most were from deceased donors (86%). VRE infection occurred at a median of 21 days after LT, and 16% had known prior VRE colonization. Common infection sites were blood (45%, n = 19), intraabdominal (36%, n = 15), and urine (36%, n = 15). Most were initially treated with daptomycin alone (64%) or in combination with other agents (21%); 7% received linezolid alone. Twelve (29%) developed breakthrough infections during treatment and 11 (26%) had recurrent infections after discontinuation of treatment. All‐cause mortality was 36% ( n = 15) at a median of 90 days after VRE infection diagnosis and was nearly twice as high in patients with DR (63%). Conclusion VRE infection in LT recipients relapsed or recurred in over 25%. Mortality was high, especially in cases with DR. More data is needed to establish an optimal treatment approach, particularly for relapse and DR. image
科研通智能强力驱动
Strongly Powered by AbleSci AI